Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients FDAThe U.S.Gene Therapy PlatformRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) FDA The U.S. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay offNext: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
